Mersana Therapeutics Inc (MRSN)
1.96
+0.12
(+6.52%)
USD |
NASDAQ |
Nov 05, 14:42
Mersana Therapeutics Total Liabilities (Quarterly): 170.70M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 170.70M |
| March 31, 2024 | 170.39M |
| December 31, 2023 | 189.16M |
| September 30, 2023 | 210.71M |
| June 30, 2023 | 221.20M |
| March 31, 2023 | 231.90M |
| December 31, 2022 | 242.28M |
| September 30, 2022 | 224.62M |
| June 30, 2022 | 118.32M |
| March 31, 2022 | 117.74M |
| December 31, 2021 | 84.37M |
| September 30, 2021 | 62.04M |
| June 30, 2021 | 58.17M |
| March 31, 2021 | 49.97M |
| December 31, 2020 | 45.31M |
| September 30, 2020 | 36.82M |
| Date | Value |
|---|---|
| June 30, 2020 | 36.95M |
| March 31, 2020 | 32.77M |
| December 31, 2019 | 29.22M |
| September 30, 2019 | 28.61M |
| June 30, 2019 | 30.87M |
| March 31, 2019 | 25.32M |
| December 31, 2018 | 69.71M |
| September 30, 2018 | 64.52M |
| June 30, 2018 | 61.22M |
| March 31, 2018 | 59.21M |
| December 31, 2017 | 60.72M |
| September 30, 2017 | 59.27M |
| June 30, 2017 | 156.87M |
| March 31, 2017 | 63.87M |
| December 31, 2016 | 160.71M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
29.22M
Minimum
Dec 2019
242.28M
Maximum
Dec 2022
122.77M
Average
117.74M
Median
Mar 2022
Total Liabilities (Quarterly) Benchmarks
| Chimerix Inc | 22.93M |
| Cellectar Biosciences Inc | 17.00M |
| Marinus Pharmaceuticals Inc | 134.43M |
| Jaguar Health Inc | 44.88M |
| Seres Therapeutics Inc | 408.80M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 179.13M |
| Shareholders Equity (Quarterly) | 8.427M |
| Debt to Equity Ratio | 3.012 |
| Current Ratio | 2.717 |
| Net Debt Paydown Yield | -0.03% |